Form 4: TransMedics Group Director James Tobin Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Director James Tobin sold shares of TransMedics Group, Inc. (TMDX) on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- James R. Tobin, a director of TransMedics Group, Inc., sold shares of the company's common stock on March 1, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on November 21, 2023.
- The transactions involved multiple sales at varying prices, ranging from $81.41 to $85.55 per share.
- A total of 14,373 shares were sold.
- The sales were conducted both directly and indirectly through the James R. Tobin 2012 Trust.
- Following the reported transactions, the James R. Tobin 2012 Trust beneficially owns 220,211 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.
Industry Context
Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The share sales could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-11-21 | Date of adoption of the Rule 10b5-1 trading plan |
| 2024-03-01 | Date of the reported transactions (share sales) |
| 2024-03-05 | Date of signature of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.